Chronic Mountain Sickness
Conditions
Interventions
Control group:None
CMS group:None
Sponsors
Institute of Cardiovascular Diseases of PLA, Xinqiao Hospital, Army Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Control group: (1) Aged over 18 years, male or female; (2) Those who live on high altitude over 1 year and not intented to return to the plains for permanent residence during the study period; (3) Without chronic mountain sickness (Qinghai CMS criteria); (4) Sign informed consent voluntarily. 2. CMS group: (1) Aged over 18 years, male or female; (2) Those who live on high altitude over 1 year and not intented to return to the plains for permanent residence during the study period; (3) Diagnosed with chronic mountain sickness (Qinghai CMS criteria); (4) Sign informed consent voluntarily.
Exclusion criteria
Exclusion criteria: 1. Control group: (1) Women who are pregnant, breastfeeding, or intended to become pregnant during the study period; (2) Smokers, alcohol drinkers and drug abusers; (3) Those with a clear history of drug allergies; (5) Patients with cardiovascular and cerebrovascular diseases, respiratory diseases, mental diseases, diabetes, hyperthyroidism and other metabolic diseases, as well as cancer and other life-threatening diseases with an expected survival time of less than 12 months; (5) Those who have participated in clinical trials of other drugs within 1 month; (6) Those who prepare to take blood-activating, immune-enhancing and antioxidant drugs for a long time. 2. CMS group: (1) Women who are pregnant, breastfeeding, or intended to become pregnant during the study period; (2) Smokers, alcohol drinkers and drug abusers; (3) Those with a clear history of drug allergies; (4) Diagnosis of other cardiovascular disease prior to confirmation of CMS (5) Patients with cardiovascular and cerebrovascular diseases, respiratory diseases, mental diseases, diabetes, hyperthyroidism and other metabolic diseases, as well as cancer and other life-threatening diseases with an expected survival time of less than 12 months; (6) Those who have participated in clinical trials of other drugs within 1 month; (7) Those who prepare to take blood-activating, immune-enhancing and antioxidant drugs for a long time.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Myocardial injury markers;Heart failure markers;Chest X ray;Echocardiography;Ambulatory blood pressure;Ambulatory ECG;Oxygen saturation;Cardiac magnetic resonance;Myocardial perfusion imaging;Right heart catheterization; | — |
Secondary
| Measure | Time frame |
|---|---|
| Blood routine examination;Blood biochemistry markers;Heart rate;Other laboratory biomarker;Routine urine test; | — |
Countries
China
Contacts
Public ContactHuang Lan
Second Affiliated Hospital, Army Military Medical University
Outcome results
None listed